Digestive Diseases and Sciences

, Volume 57, Issue 6, pp 1469–1474 | Cite as

Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues

  • Jason E. Bonner
  • A. Sidney BarrittIV
  • Michael W. Fried
  • Donna M. Evon



A new era has dawned in the treatment of chronic hepatitis C (HCV) virus with the use of direct-acting antiviral medications augmenting combination therapy. Unfortunately, the significant impact of improvements may not be realized if antiviral treatment is not expanded to include a larger proportion of patients, many of whom have coexisting mental health and/or substance abuse issues and have been historically deferred from treatment.


We reviewed the extent literature on HCV treatment for individuals with co-occurring mental health and/or substance abuse issues.


A number of empirically-based arguments exist in favor of treating HCV-infected individuals with mental health and/or substance abuse issues within the context of multidisciplinary team approaches. Integrated, collaborative, or hybrid models of care are just a few examples of multidisciplinary approaches that can combine the care of HCV treating providers with mental health and/or addictions providers to safely and effectively treat these patients. Collectively, these arguments and the empirical evidence that supports them, provides a strong rationale for why expanding antiviral therapy to these patients is critical and timely.


A decade of evidence suggests that HCV-infected individuals with mental health and/or substance abuse issues can safely and effectively undergo antiviral treatment when delivered through multidisciplinary care settings. Multidisciplinary approaches that combine HCV treating providers with mental health, addictions, and other support systems can facilitate preparation and successful treatment of these patients on antiviral therapy.


Psychiatric Depression Substance abuse Multidisciplinary 



American Association for the Study of Liver Diseases


Chronic hepatitis C virus


Mental health/substance abuse


Sustained virological response



Donna Evon receives research grant support from Roche, and served on an advisory board for Vertex Pharmaceuticals in the past 12 months. Michael Fried has had research grant funding and has served as ad hoc consultant for Roche. Dr. Fried also serves as ad hoc consultant to Vertex, Merck, Tibotec, Pharmasset, GlaxoSmithkline, and Gilead. Sid Barritt is on the speaker’s bureau for Salix Pharmaceuticals and receives research grant support from Tibotec. This work was supported, in part, by a UNC Clinical and Translational Science Award (UL1RR025747; Bonner); the National Institutes of Health Awards (1KL2-RR025746-03; Barritt; and K23DK089004-02; Evon) and a mentoring grant (K24 DK066144-01; Fried).

Conflict of interest

Dr. Bonner has nothing to disclose.


Dr. Fried receives research grants from Genentech, Vertex, Tibotec, Janssen, Gilead, Abbott, BristolMyers Squibb, Anadys. He serves as an ad hoc consultant to Genentech, Vertex, Merck, Tibotec, Janssen, BristolMyers Squibb, Novartis, Gilead.


  1. 1.
    Jacobsen IM, McHutchison JG, Dusheiko GM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.Google Scholar
  2. 2.
    Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–1024.Google Scholar
  3. 3.
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.Google Scholar
  4. 4.
    Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521.PubMedCrossRefGoogle Scholar
  5. 5.
    Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother. 2010;65:1327–1329.PubMedCrossRefGoogle Scholar
  6. 6.
    Deuffic-Burban S, Poynard T, Sulkowski MS, et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14:107–115.PubMedCrossRefGoogle Scholar
  7. 7.
    El-Serag HB, Talwalkar J, Kim WR. Efficacy, effectiveness, and comparative effectiveness in liver disease. Hepatology. 2010;52:403–407.PubMedCrossRefGoogle Scholar
  8. 8.
    Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci. 2007;52:3251–3258.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36:S30–S34.PubMedCrossRefGoogle Scholar
  10. 10.
    Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777–782.PubMedCrossRefGoogle Scholar
  11. 11.
    Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS. 2005;19:S227–S237.PubMedCrossRefGoogle Scholar
  12. 12.
    Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–2262.PubMedCrossRefGoogle Scholar
  13. 13.
    Hill WD, Butt G, Alvarez M, et al. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol. 2008;22:27–32.PubMedGoogle Scholar
  14. 14.
    Zaller N, Gillani FS, Rich JD. A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness. AIDS Care. 2007;19:1128–1133.PubMedCrossRefGoogle Scholar
  15. 15.
    Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52:1124–1133.PubMedCrossRefGoogle Scholar
  16. 16.
    Fireman M, Indest DW, Blackwell A, et al. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis. 2005;40:S286–S291.PubMedCrossRefGoogle Scholar
  17. 17.
    Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.PubMedCrossRefGoogle Scholar
  18. 18.
    United States Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, & treatment of viral hepatitis. [Department of Health and Human Services web site]. 2011. Available at: Accessed May 12, 2011.
  19. 19.
    Gilfillan RJ, Tomcavage J, Rosenthal MB, et al. Value and the medical home: effects of transformed primary care. Am J Manag Care. 2010;16:607–614.PubMedGoogle Scholar
  20. 20.
    Goldberg RW. Supported medical care: a multi-faceted approach to helping HIV/hepatitis C virus co-infected adults with serious mental illness. AIDS. 2005;19:S215–S220.PubMedCrossRefGoogle Scholar
  21. 21.
    Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22:270–277.PubMedCrossRefGoogle Scholar
  22. 22.
    Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health. 2004;81:719–734.PubMedCrossRefGoogle Scholar
  23. 23.
    Arora S. Project ECHO: knowledge networks for the treatment of complex diseases in remote, rural, underserved communities. 2007. Available at: Accessed August 29, 2011.
  24. 24.
    Bellentani S, Dalle GR, Suppini A, et al. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008;47:746–754.PubMedCrossRefGoogle Scholar
  25. 25.
    Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.PubMedCrossRefGoogle Scholar
  26. 26.
    Pattullo V, Fernandes GS, Sockalingam S, et al. A 24-week dietary and physical activity intervention leads to sustained improvements in body mass index and insulin resistance in the obese with insulin resistant chronic hepatitis C. J Gastroenterol Hepatol. 2010;25:A120–A136.Google Scholar
  27. 27.
    Lackner JM, Jaccard J, Krasner SS, et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol. 2008;6:899–906.PubMedCrossRefGoogle Scholar
  28. 28.
    Lackner JM, Jaccard J, Krasner SS, et al. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology. 2007;133:433–444.PubMedCrossRefGoogle Scholar
  29. 29.
    Blanchard EB, Lackner JM, Sanders K, et al. A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther. 2007;45:633–648.PubMedCrossRefGoogle Scholar
  30. 30.
    Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011;106:1777–1786.PubMedCrossRefGoogle Scholar
  31. 31.
    Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34:268–271.PubMedCrossRefGoogle Scholar
  32. 32.
    Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.PubMedGoogle Scholar
  33. 33.
    Butt AA, Wagener M, Shakil AO, et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat. 2005;12:81–85.PubMedCrossRefGoogle Scholar
  34. 34.
    Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction. 2004;99:1167–1175.PubMedCrossRefGoogle Scholar
  35. 35.
    Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443–451.PubMedCrossRefGoogle Scholar
  36. 36.
    Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42:793–798.PubMedCrossRefGoogle Scholar
  37. 37.
    Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology. 2007;46:991–998.PubMedCrossRefGoogle Scholar
  38. 38.
    Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18:437–443.PubMedCrossRefGoogle Scholar
  39. 39.
    Sylvestre DL, Litwin AH, Clements BJ, et al. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat. 2005;29:159–165.PubMedCrossRefGoogle Scholar
  40. 40.
    Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19:741–747.PubMedCrossRefGoogle Scholar
  41. 41.
    Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis. 2005;40:S325–S329.PubMedCrossRefGoogle Scholar
  42. 42.
    Freedman K, Nathanson J. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders. Expert Rev Anti Infect Ther. 2009;7:363–376.PubMedCrossRefGoogle Scholar
  43. 43.
    Zanini B, Covolo L, Donato F, et al. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther. 2010;32:2139–2159.PubMedCrossRefGoogle Scholar
  44. 44.
    Bruggmann P, Dampz M, Gerlach T, et al. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend. 2010;110:167–171.PubMedCrossRefGoogle Scholar
  45. 45.
    Bruggmann P, Falcato L, Dober S, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008;15:747–752.PubMedCrossRefGoogle Scholar
  46. 46.
    Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755.PubMedCrossRefGoogle Scholar
  47. 47.
    Lopez-Navas A, Rios A, Riquelme A, et al. Psychological characteristics of patients on the liver transplantation waiting list with depressive symptoms. Transplant Proc. 2011;43:158–160.PubMedCrossRefGoogle Scholar
  48. 48.
    DiMartini A, Dew MA, Javed L, et al. Pretransplant psychiatric and medical comorbidity of alcoholic liver disease patients who received liver transplant. Psychosomatics. 2004;45:517–523.PubMedCrossRefGoogle Scholar
  49. 49.
    Rocca P, Cocuzza E, Rasetti R, et al. Predictors of psychiatric disorders in liver transplantation candidates: logistic regression models. Liver Transpl. 2003;9:721–726.PubMedCrossRefGoogle Scholar
  50. 50.
    Butt AA, McGinnis KA, Skanderson M, et al. Hepatitis C treatment completion rates in routine clinical care. Liver Int. 2010;30:240–250.PubMedCrossRefGoogle Scholar
  51. 51.
    Zacks S, Beavers K, Theodore D, et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol. 2006;40:220–224.PubMedCrossRefGoogle Scholar
  52. 52.
    Zickmund S, Ho EY, Masuda M, et al. “They Treated Me Like a Leper”: stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–844.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jason E. Bonner
    • 1
  • A. Sidney BarrittIV
    • 1
  • Michael W. Fried
    • 1
  • Donna M. Evon
    • 1
  1. 1.Division of Gastroenterology and Hepatology, Department of MedicineUniversity of North CarolinaChapel HillUSA

Personalised recommendations